Observational studyMedicine2025
Prognostic factors for poor outcomes and the predictive role of circulating tumor DNA in immunotherapy for advanced non-small cell lung cancer.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced non-small cell lung cancer (NSCLC) demonstrates considerable variability in therapeutic response. Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for predicting immunotherapy efficacy and progression-free survival (PFS). This study investigates the prognostic relevance of ctDNA levels along with other clinical parameters in patients treated with immune checkpoint inhibitors. A retrospective analysis was conducted on 118 patients with stage IIIB/IV NSCLC who received Tislelizumab between January 2021 and December 2023 at Quanzhou First Hospital. ctDNA concentrations were assessed before and after treatment using quantitative polymerase chain reaction (qPCR). Based on RECIST 1.1 criteria, patients were classified into the responder group (complete or partial response) and the nonresponder group (stable or progressive disease). Statistical methods included receiver operating characteristic curve analysis, Kaplan-Meier survival estimates, and Cox proportional hazards regression. Posttreatment ctDNA levels were significantly lower in responders compared with nonresponders (2.72 ± 1.11 vs 4.18 ± 1.54 ng/μL, P < .001). Receiver operating characteristic analysis yielded an AUC of 0.821, with sensitivity and specificity of 80.9% and 79.8% at a cutoff value of 3.59 ng/μL. Kaplan-Meier analysis demonstrated that patients with low ctDNA had longer median PFS (8.6 months) than those with high ctDNA (5.5 months, P < .001). Multivariate Cox regression identified ctDNA levels and treatment modality as independent predictors of PFS. ctDNA serves as a reliable predictor of immunotherapy response and PFS in advanced NSCLC. Incorporating ctDNA monitoring into routine practice may enhance patient stratification and optimize therapeutic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.